Pfizer recalls newly acquired pain drug Embeda
This article was originally published in Scrip
Executive Summary
Pfizer was dealt a bad hand this month when its newly acquired subsidiary King Pharmaceuticals voluntarily recalled all lots of its opioid analgesic Embeda (morphine sulfate and naltrexone hydrochloride) after a problem with the drug's stability was detected.